Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers the month of July 2024, with the report dated July 2, 2024. The company is a foreign private issuer based in Hoersholm, Denmark, focused on vaccine development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material corporate agreement rather than financial performance data.
Material Changes
On June 27, 2024, the Company entered into an updated CAF® 09b Patent, Know How & Trademark License Agreement with SSI. This new agreement replaces the original agreement dated November 30, 2020. Key updates include:
- Grant of an exclusive, royalty-bearing, sub-licensable license.
- Coverage of a product comprising SSI's adjuvant technology CAF® 09b and PIONEER identified neopeptides.
- Improved commercial terms for the Company compared to the prior agreement.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the description of the license agreement. The agreement itself is filed as Exhibit 10.1 and is incorporated by reference into various registration statements (Forms S-8, F-3, and F-1).
Investor Verification Checklist
- Review Exhibit 10.1 (License Agreement) for specific details on royalty rates and commercial terms.
- Verify the scope of the "PIONEER identified neopeptides" included in the license.
- Confirm the impact of the updated agreement on the Company's existing pipeline and potential revenue streams.
- Check subsequent filings for any financial impact resulting from this agreement.